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Abstract
Background:  Informed consent is an ethical and legal requirement for research involving human
participants. However, few studies have evaluated the process, particularly in Africa.
Participants in a case control study designed to identify correlates of immune protection against
tuberculosis (TB) in South Africa. This study was in turn nested in a large TB vaccine efficacy trial.
The aim of the study was to evaluate the quality of consent in the case control study, and to identify factors
that may influence the quality of consent.
Cross-sectional study conducted over a 4 month period.
Methods: Consent was obtained from parents of trial participants. These parents were asked to complete
a questionnaire that contained questions about the key elements of informed consent (voluntary
participation, confidentiality, the main risks and benefits, etc.). The recall (success in selecting the correct
answers) and understanding (correctness of interpretation of statements presented) were measured.
Results: The majority of the 192 subjects interviewed obtained scores greater than 75% for both the
recall and understanding sections. The median score for recall was 66%; interquartile range (IQR) = 55%–
77% and for understanding 75% (IQR = 50%–87%). Most (79%) were aware of the risks and 64% knew that
they participated voluntarily. Participants who had completed Grade 7 at school and higher were more
likely (OR = 4.94; 95% CI = 1.57 – 15.55) to obtain scores greater than 75% for recall than those who did
not. Participants who were consented by professional nurses who had worked for more than two years
in research were also more likely (OR = 2.62; 95% CI = 1.35–5.07) to obtain such scores for recall than
those who were not.
Conclusion: Notwithstanding the constraints in a developing country, in a population with low levels of
literacy and education, the quality of informed consent found in this study could be considered as building
blocks for establishing acceptable standards for public health research. Education level of respondents and
experience of research staff taking the consent were associated with good quality informed consent.
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Background
Informed consent is an ethical and legal requirement for
research involving human participants [1]. Guidelines as
contained in the Declaration of Helsinki, the Nuremburg
Code and the Belmont Report [2], and the Council for the
International Organizations of Medical Research [3] have
become accepted tools used by Institutional Review
Boards (IRBs), the bodies responsible for ethical review of
research proposals, in approving such research. The Inter-
national Convention for Harmonization's initiative on
Good Clinical Practice (GCP) [4] is considered to be the
quality standard for the conduct of clinical trials in
humans. Accredited courses for investigators of clinical
trials are based on these GCP guidelines. Medical doctors,
professional nurses, and other health professionals who
conduct research on behalf of principal investigators fre-
quently do these courses as part of their training.
In most countries research ethics are regulated by statu-
tory bodies [5,6]. IRBs of sponsor organizations and
Research Ethics Committees (RECs) of academic institu-
tions are mandated by their stakeholders to protect partic-
ipants.
However, unethical research practices occur not uncom-
monly and appear to have been accepted and even perpet-
uated by IRBs [7-9]. Some authors have reservations about
the capabilities of IRBs in developing countries, suggest-
ing that they may be made up by inadequately skilled
members [10]. London [11] proposed ways to improve
the regulation of ethics practices in developing countries,
which included proper research ethics training of IRB
members and independent monitoring of research activi-
ties.
Studies of the quality of informed consent in medical
practice have found this to be poor [12-14]. Similar short-
comings in consent quality in research have been found
[15-17], particularly in developing countries, where con-
cepts such as "voluntary participation [18,20]", "rand-
omization [19]" and "benefits and risks [20]" may have
variable interpretations. Large scale research projects are
increasingly being conducted in these settings. The
informed consent process poses several challenges, logis-
tic as well as ethical, since failures of informed consent
may result in the violations of participants' human rights.
In South Africa, where the rights of the research partici-
pant are explicitly protected in the Constitution [6], it is
essential that this understanding of participants' rights be
tested in the appropriate research environment. Poverty,
disease, lack of education, hardship, submissiveness, the
effects of war, famine, pandemics, and social insecurity
prevalent in developing countries all make participants
more vulnerable to research exploitation.
Purpose & objectives
This secondary study, the "consent study", aimed to eval-
uate the quality of informed consent in a primary case
control study (the Immunology Study) of immune corre-
lates of protection against severe childhood TB nested
inside a randomized controlled trial vaccine trial [Bacille
Calmette-Guerrin (BCG) Study]. A total of 5467 children
were enrolled into the Immunology Study from 2001 to
2004. These studies were implemented in Worcester, a
rural setting in the Western Cape Province of South Africa.
Participants in the primary immunology case control
study underwent collection of blood between 8 and 14
weeks of age, after written consent had been obtained
from their parents. The consent procedure was concluded
by means of signing a consent form.
The objectives of this consent study were:
a. To determine study participants' recall and understand-
ing of items discussed during the consent procedure for
the immunology study;
b. To establish whether certain participant and study-
related factors were associated with the quality of
informed consent; and
c. To describe the association between the quality of
informed consent and participants' knowledge of their
health rights.
Methods
The study was a cross-sectional study conducted over four
months
Population and sampling
The population for the consent study was drawn from
mothers who gave informed consent for the participation
of their children in the Immunology Study. Recruitment
for the Immunology Study took place from March to June
2004 in the form of a team visiting district health facilities
according to a fixed schedule. Enrolment and phlebotomy
were preceded by a booking session at which an informa-
tion pamphlet about the Immunology study was handed
out. Informed consent was conducted in the first language
of the mother (either Afrikaans or Xhosa) by trained inter-
viewers.
For the consent study, all mothers attending clinics where
the language of communication was predominantly
Xhosa, and every fourth mother attending Afrikaans-lan-
guage clinics were approached to participate in the con-
sent study.BMC Medical Ethics 2008, 9:15 http://www.biomedcentral.com/1472-6939/9/15
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Dedicated nursing staff conducted the interview within
one hour of mothers' consent to their infant's participa-
tion in the Immunology Study.
Measurement and data collection
The quality of informed consent was determined by meas-
uring the recall and understanding of informed consent
using a questionnaire specifically designed for this study
(see additional file 1). The questionnaire contained nine
questions dealing with the basic facts of the Immunology
Study. Participants were expected to select the correct
answer from a choice of three possible answers for each of
the questions. One of the answers was an exact reflection
of the information in the consent document, which, if
selected, was taken as an indicator of correct recall. For the
understanding assessment, participants were expected to
select the appropriate interpretations for a total of eight
statements offered. This was taken as an indication of the
extent to which participants' decisions were based on
understanding. Although there is some inevitable overlap
between recall and understanding, the type of questions
allowed broad categorization into two separate scales for
recall and understanding. Participants were requested to
complete the questionnaire in writing while consent study
staff provided assistance with the interpretation of the
questions.
Statistical methods
The results on the data form were captured, processed and
analysed using Stata version 6 [21]. Correct scores for
recall and understanding were totaled for individual par-
ticipants and summary statistics were calculated. Total
scores for individual recall and health rights questions
were also calculated. Logistic regression analyses were per-
formed to model the effect of maternal age, education,
access to telephones, language preference and research
experience of the professional nurse on the recall and
understanding scores.
Ethical considerations
The Research Ethics Committee of the University of Cape
Town Health Sciences faculty approved both the Immu-
nology and Consent Studies. Mothers who had consented
to participation into the Immunology Study were referred
to the nurse for the Consent Study in a separate room. As
part of the consent procedure, the nurse handed the
mother an information sheet written in simple language
explaining the Consent Study, and asked the mother to
read it. After verifying that the mother understood the
contents of the consent letter, she was then asked to par-
ticipate. If she accepted, the nurse asked the mother to
acknowledge by signing and dating a copy of the letter.
This copy was kept for record purposes.
Results
Four hundred and eighty-one participants from 106 clinic
visits to 22 primary healthcare facilities (clinics) in the
study area were enrolled into the Immunology Study. Of
the 32 visits which were selected for the Consent Study,
two visits were cancelled. A total of 202 Immunology
Study participants were referred to the Consent Study
staff. One-hundred-and-ninety-two (192) mothers com-
pleted the questionnaires for the Consent Study, resulting
in a response rate of 95.0% (Figure 1). The non-respond-
ers were made up as follows: three left the clinic before the
Consent Study team had started enrollments, four could
not be enrolled because of an accidental language mis-
match and a further three used spoilt versions of the ques-
tionnaire. The demographic characteristics of the sample
are listed in Table 1.
Participants obtained a median score of 66.7% (range
11.1% – 100.0%) in the recall and 75.0% (range 37.5% –
100%) in the understanding sections. Both scores were
skewed towards the left (Figures 2, 3). Although only 12
(6%) and 25 (13%) of participants respectively had all the
answers to the recall and understanding questions correct,
the majority of participants obtained scores in the "75%
or greater" category. Only 3 (1.6%) obtained a score of
less than 25% for the recall test and none had two or fewer
correct out of eight understanding questions. As can be
seen from Table 2, higher levels of recall scores were pos-
Schema to show how participants were selected for the con- sent study Figure 1
Schema to show how participants were selected for 
the consent study. Of the 106 Immunology Study visits 
("phlebotomy clinics") scheduled for the study period, 32 
were selected through systematic sampling. A total of 481 
participants enrolled for the Immunology Study during the 
corresponding period. Of these, 202 were eligible to partici-
pate in the consent study. Eventually, 192 participants com-
pleted the consent study questionnaire.
Number of actual consent study visits: 30
Number of completed questionnaires 192
Number of visits selected for the consent study: 32
Consent study sample size 202
Number of visits scheduled for the Immunology Study: 106
Immunology study participants 481
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itively associated with higher levels of understanding lev-
els scores (Spearman correlation coefficient = 0.37, p =
0000).
Recall of questions: Four out of the nine recall questions
elicited more than 75% correct answers (Table 3), and
another four elicited between 50% and 75% correct
answers. The question used to test whether participants
knew the reason for the clinic visit received the highest
proportion (85.4%) of correct answers (Figure 4). Nota-
bly, only 36.5% of participants knew that there were no
immediate benefits. Otherwise, correct responses
exceeded 60% for other questions.
The final logistic regression model obtained for recall
scores of 75% or greater included experience of research
nurse and education level of the participant. Participants
who had completed Grade 7 and higher at school were
more likely (OR = 4.94, 95% CI = 1.57–15.55) to obtain
a minimum of 75% in the recall test compared to partici-
pants who did not progress that far in education. Also,
consent obtained by nurses with more than two years
research experience resulted in an almost three times (OR
= 2.62, 95% CI = 1.35 – 5.07) the odds of scoring at least
75% compared to nurses with less than two years of expe-
rience.
Understanding of questions: Most participants gave the
expected answers (Table 4) for all understanding ques-
tions. Although 87.5% of participants understood that the
development of a bruise did not warrant a call to the
police, a relatively low percentage (66.2%) knew that they
could discuss the bruise with the nurse at the clinic. The
logistic regression model obtained for understanding
scores of 75% and greater indicated that participants who
were older than the median ages of 26 years were more
likely (95% CI = 1.15 – 4.07) to obtain high scores than
those younger than 26 years. Level of education was not
associated with understanding in this model.
Knowledge of health rights as contained in the South Afri-
can Constitution (see figure 5): The majority of partici-
pants were aware of their rights regarding access to health
care, freedom of choice and freedom from harm. How-
ever, confidentiality of information and free health care
for all were mistaken as rights by most participants. The
overall score for health rights was not linearly correlated
with either the recall or the understanding assessment
(Spearman's correlation coefficient not greater than |0.10|
and p = 0.96 and 0.41, respectively). Individual scores for
each of the health rights also had no association with the
recall scores, and all but one of the understanding scores.
The knowledge of right to freedom of choice was associ-
ated with the understanding score (OR = 2.59, 95% CI =
1.06 – 6.34).
Discussion
The finding that most participants obtained scores in
excess of 75% for understanding and 66% for recall indi-
cates that the general quality of informed consent was
encouraging. Almost all participants felt that they would
participate again in a similar study if they were given the
choice. These results are similar to both qualitative and
quantitative findings in previous studies conducted in
developing countries [18,20,22].
Table 1: Demographic characteristics (n = 192)
Participant aspect Consent Study
Age (years): median (range) 26 (16–44)
Language: % Afrikaans 56.8
% Xhosa 43.2
Level of education: (% Grade 6 or less) 23.4
(% Grade 7 to 11) 42.8
(% Grade 12 or higher) 33.9
Access to a telephone: (%) 57.9
Attendance per clinic: median (range) 8 (1–15)
Table 2: Relationship between recall and understanding score (n = 192)
Understanding n (%)
High* High medium* Low medium* Low*
Recall n (%)
High* 76
(80.0%)
17
(17.9%)
2
(2.1%)
0
(0.0%)
High medium* 39
(57.3%)
25
(36.8%)
4
(5.9%)
0
(0.0%)
Low medium* 14
(53.9%)
11
(42.3%)
1
(3.9%)
0
(0.0%)
Low* 1
(33.3%)
2
(66.7%)
0
(0.0%)
0
(0.0%)
* High: [≥ 75%]; High medium: [≥ 50% & < 75%]; Low medium: [≥ 25% & < 50%]; Low: [< 25%]BMC Medical Ethics 2008, 9:15 http://www.biomedcentral.com/1472-6939/9/15
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The proportion of participants with low scores for quality
of informed consent was small and lower even than that
found in some studies in industrialized countries [16,23].
However, due to differences in methodologies, no specific
comparison is attempted. The understanding assessment
result supports earlier suggestions [24] that low levels of
education need not hinder participants' ability to under-
stand consent concepts.
It is reassuring that the two language groups had similar
results, as there had been concerns in the trial that consent
quality would be different between the language groups.
The two languages broadly represent two different race
groups in South Africa, which could be associated with
differences in perception of social services such as health
care. Barsdorf & Wassenaar [25] have shown that Black
participants, known to have suffered most from the injus-
tices of the apartheid regime, had poorer perception of
voluntariness than their White and Indian counterparts.
These differences in perceptions of research between race
groups were not demonstrated in this study.
Some limitations in the measurement method are evi-
dent. The study did not assess the ability of participants to
retain information for longer periods of time (i.e. days,
weeks or months) after their enrolment into the Immu-
nology Study. Moreover, the questions posed for under-
standing could not cover all the emotional and
intellectual aspects involved when giving consent. Access
to a telephone or cell-phone may not be the best proxy for
socioeconomic status as it may be too indirect and focuses
only on the "economic" part of status. There is also an
unquantifiable overlap between recall and understanding.
Nonetheless, despite the recognized difficulties of meas-
uring understanding with informed consent procedures,
the findings of this study pointed to the need to employ
methods to enhance informed consent quality in less edu-
cated participants, such as the use of audiovisual aids.
The following are required for a good consent quality: a
much greater focus on the consent process, the assurance
that participants possess the required level of education
(in South Africa Grade 7 is considered minimum), that
voluntary participation is encouraged and that confidenti-
ality is secured. In addition, an abridged form of self-
assessment by participants, such as the type described in
this study, could improve the general understanding of
research concepts, such as voluntary participation and
confidentiality by prospective research participants. A sec-
ond and third attempt at explaining some of the more dif-
ficult concepts might help to ensure better recall and
understanding of information.
We suggest that research ethics committees should insist
on periodic reports on consent quality and efforts to
improve quality where appropriate as part of their respon-
sibility to protect the public against unethical research
practices. The Consent Study focused on the evaluation of
the quality of informed consent by using a self-adminis-
tered questionnaire. Although level of education and
experience of the research staff were predictors of good
quality of consent in this study, researchers would need to
identify the predictors of good quality consent in their
studies. Although this study chose to weight recall and
understanding equally, consideration could be given to
whether specific questions, such as those pertaining to
perceived benefits or ability to withdraw, should have
Distribution of the results (scores out of 9) of the recall test Figure 2
Distribution of the results (scores out of 9) of the 
recall test.
Distribution of the results (scores out of 8) of the under- standing test Figure 3
Distribution of the results (scores out of 8) of the 
understanding test.BMC Medical Ethics 2008, 9:15 http://www.biomedcentral.com/1472-6939/9/15
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Table 3: Results of quality of informed consent assessment: Recall section
1. I have been asked to attend the clinic today so that (n = 192):
My baby can participate in a research study 164 (85.4%)
My baby can receive expert treatment. 14 (7.3%)
My baby can receive routine health care 14 (7.3%)
2. The purpose of the research study is to (n = 191):
Test for protection against tuberculosis in my baby's blood. 154 (80.6%)
Test for tuberculosis in my baby's blood 35 (18.3%)
Test for HIV in my baby's blood 2 (1.1%)
3. Research staff wants to enroll my baby into the research study so that (n = 189):
They can collect blood from my baby 115 (60.9%)
They can inject my baby with BCG 40 (21.1%)
They can test my baby for TB or HIV 34 (18.0%)
4. The total amount of time my baby will be expected to participate in the study is (n = 190):
1 day 126 (66.3%)
2 to 3 years 45 (23.7%)
8 to 14 weeks 19 (10.0%)
5. The most common risk involved when blood had been collected from my baby is (n = 192):
My baby may suffer very slight scarring and some oozing 152 (79.2%)
My baby can become infected with TB or HIV 35 (18.2%)
My baby can loose too much blood 5 (2.6%)
6. The benefits available to me and my baby for participating in the study are (n = 191):
My baby will be protected against TB 98 (51.3%)
There are no immediate benefits 70 (36.7%)
My baby and I will get better treatment at clinics 23 (12.0%)
7. If I didn't want to participate in this study, I could withdraw and (n = 189)
My baby and I would suffer no loss at all 123 (65.1%)
My baby and I will be treated differently by research and clinic staff 47 (24.9%)
My baby and I would be denied access to health services at this clinic 19 (10.0%)
8. My baby's personal details will never be linked with her blood because (n = 191)
Numbers with barcodes will be used to keep bloods anonymous 140 (73.3%)
Highly trained research staff will keep information secret 40 (20.9%)
Clinic staff will be sure not to give information to the research staff 11 (11.8%)
9. The blood of my baby that will be frozen and stored will be used (n = 187)
For other tests concerning protection against TB 155 (82.9%)
For all kinds of research in other countries 29 (15.5%)
For HIV testing 3 (1.6%)
Correct answers based on information provided as part of the consent process in italics and listed first here, but in normal print and distributed 
randomly in the field questionnaireBMC Medical Ethics 2008, 9:15 http://www.biomedcentral.com/1472-6939/9/15
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higher weight in deciding whether participant consent is
adequate.
The Immunology Study was conducted in a rural district
known for its low socio-economic status, high unemploy-
ment and high prevalence of diseases of poverty. Our
experience is that participants are generally research naïve,
and because of problems of staff shortage and scarce
resources in the health services, frequently confuse
research activities with health care delivery, and therefore
Overall results of the recall test Figure 4
Overall results of the recall test. The percentage of participants who provided the correct answer to each of the recall 
questions.
Table 4: Results of quality of informed consent assessment: Understanding section
I agreed to enrol my child in this study because
True False Not sure
My child might get better treatment 44.8 52.1 3.1
I want doctors to help learn more about TB 88.5 4.7 6.8
I've decided to enrol my baby in the study
Even though my baby will receive no extra treatment 73.4 19.3 7.3
Because I knew I would receive a toiletries hamper 13.0 80.7 6.3
If my baby gets a bruise from the blood test, I should
Contact the police 5.7 87.5 6.8
Speak to the nurse at the clinic 68.2 30.7 1.1
Go to the doctor at his private surgery 22.4 66.2 11.4
If I was given the choice to participate again, I would 90.6 3.1 6.3
Correct interpretation, according to the information provided during the consent process, in bold type here, but in normal print in the field 
questionnaire.BMC Medical Ethics 2008, 9:15 http://www.biomedcentral.com/1472-6939/9/15
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welcome the attention of better resourced research initia-
tives. This renders them a particularly vulnerable research
population. Given this context, the findings of the Con-
sent Study can be considered encouraging, in particular
because it appears as if most participants had made
informed choices about their participation in the Immu-
nology Study. Most participants had medium to high
understanding of the study. Misunderstanding about per-
ceived benefits is understandable, but it could also mean
that participants made the decision to participate in the
Immunology Study because of a belief that the benefits
were greater than they actually were.
Conclusion
This study should add to the sparse literature dealing with
the quantitative evaluation of informed consent in a
developing country situation, and encourage commentary
and further research in this important area of research eth-
ics, including further exploration into the question of
acceptable standards for quality of informed consent.
While developed country-based sponsors are likely to be
centrally concerned with the scientific question, and
research ethics committees about the general ethical con-
duct of proposed research, principal investigators in
developing countries should consciously consider attain-
ing good quality informed consent as a key component of
their research proposals.
In this study, good quality informed consent was associ-
ated with higher levels education of respondents and
experience of staff obtaining the consent. Many research
studies are conducted in developing countries in similar
settings, i.e. where there are language and cultural differ-
ences between researchers and participants, low education
and socio-economic status and limited resources. There is
therefore no reason that the same quality of informed
consent should not be achieved in other parts of Southern
Africa and abroad.
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